Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nose to Brain Delivery of Nanocarriers Towards Attenuation of Demented Condition

Author(s): Bapi Gorain*, Davinaa C. Rajeswary, Manisha Pandey, Prashant Kesharwani, Santosh A. Kumbhar and Hira Choudhury*

Volume 26, Issue 19, 2020

Page: [2233 - 2246] Pages: 14

DOI: 10.2174/1381612826666200313125613

Price: $65

Abstract

Increasing incidence of demented patients around the globe with limited FDA approved conventional therapies requires pronounced research attention for the management of the demented conditions in the growing elderly population in the developing world. Dementia of Alzheimer’s type is a neurodegenerative disorder, where conventional therapies are available for symptomatic treatment of the disease but possess several peripheral toxicities due to lack of brain targeting. Nanotechnology based formulations via intranasal (IN) routes of administration have shown to improve therapeutic efficacy of several therapeutics via circumventing blood-brain barrier and limited peripheral exposure. Instead of numerous research on polymeric and lipid-based nanocarriers in the improvement of therapeutic chemicals and peptides in preclinical research, a step towards clinical studies still requires wide-ranging data on safety and efficacy. This review has focused on current approaches of nanocarrierbased therapies on Alzheimer’s disease (AD) via the IN route for polymeric and lipid-based nanocarriers for the improvement of therapeutic efficacy and safety. Moreover, the clinical application of IN nanocarrier-based delivery of therapeutics to the brain needs a long run; however, proper attention towards AD therapy via this platform could bring a new era for the AD patients.

Keywords: Alzheimer's disease, intranasal, olfactory, polymeric nanoparticles, lipid-based nanocarriers, clinical perspective.

« Previous Next »
[1]
Md S, Gan SY, Haw YH, Ho CL, Wong S, Choudhury H. In vitro neuroprotective effects of naringenin nanoemulsion against β-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation. Int J Biol Macromol 2018; 118((Pt A)): 1211-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.06.190] [PMID: 30001606]
[2]
International D. World Alzheimer Report 2018 - The state of the art of dementia research: New frontiers 2018 World Alzheimer Report 2018 The state of the art of dementia research: New frontiers
[3]
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2018. 6CD001190
[http://dx.doi.org/10.1002/14651858.CD001190.pub3] [PMID: 29923184]
[4]
Cui Y-Q, Wang Q, Zhang D-M, et al. Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice. Curr Alzheimer Res 2016; 13(3): 288-96.
[http://dx.doi.org/10.2174/156720501303160217122803] [PMID: 26906357]
[5]
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71(5): 362-81.
[http://dx.doi.org/10.1097/NEN.0b013e31825018f7] [PMID: 22487856]
[6]
Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract 2015; 24(1): 1-10.
[http://dx.doi.org/10.1159/000369101] [PMID: 25471398]
[7]
Brothers HM, Gosztyla ML, Robinson SR. The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease. Front Aging Neurosci 2018; 10: 118.
[http://dx.doi.org/10.3389/fnagi.2018.00118] [PMID: 29922148]
[8]
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275(3): 251-83.
[http://dx.doi.org/10.1111/joim.12191] [PMID: 24605808]
[9]
Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009; 8(2): 144-59.
[http://dx.doi.org/10.2174/187152709787847324] [PMID: 19355934]
[10]
Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM. The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol 1968; 27(2): 167-82.
[http://dx.doi.org/10.1097/00005072-196804000-00001] [PMID: 5646193]
[11]
Thal DR, Del Tredici K, Ludolph AC, et al. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol 2011; 122(5): 577-89.
[http://dx.doi.org/10.1007/s00401-011-0871-6] [PMID: 21935637]
[12]
Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995; 10(2): 509-19.
[PMID: 7599445]
[13]
Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006; 545(1): 39-50.
[http://dx.doi.org/10.1016/j.ejphar.2006.06.026] [PMID: 16860790]
[14]
Scheff SW, Price DA. Alzheime's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006; 9(3)(Suppl.): 101-15.
[http://dx.doi.org/10.3233/JAD-2006-9S312] [PMID: 16914849]
[15]
De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell 2016; 164(4): 603-15.
[http://dx.doi.org/10.1016/j.cell.2015.12.056] [PMID: 26871627]
[16]
Lian H, Litvinchuk A, Chiang ACA, Aithmitti N, Jankowsky JL, Zheng H. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of alzheimer's disease.J Neurosci J Neurosci 2016; 36(2): 577-89.
[http://dx.doi.org/10.1523/JNEUROSCI.2117-15.2016] [PMID: 26758846]
[17]
Ries M, Sastre M. Mechanisms of Aβ clearance and degradation by glial cells. Front Aging Neurosci 2016; 8: 160.
[http://dx.doi.org/10.3389/fnagi.2016.00160] [PMID: 27458370]
[18]
Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health 2017; 2(3): e149-56.
[http://dx.doi.org/10.1016/S2468-2667(17)30031-2] [PMID: 29253388]
[19]
Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int J Pharm 2019; 565: 258-68.
[http://dx.doi.org/10.1016/j.ijpharm.2019.05.032] [PMID: 31095983]
[20]
Brooks LG, Loewenstein DA. Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther 2010; 2(5): 28.
[http://dx.doi.org/10.1186/alzrt52] [PMID: 20920147]
[21]
Edmonds EC, Delano-Wood L, Clark LR, et al. Alzheimer's Disease Neuroimaging Initiative. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 2015; 11(4): 415-24.
[http://dx.doi.org/10.1016/j.jalz.2014.03.005] [PMID: 24857234]
[22]
Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013; 6(1): 19-33.
[23]
Colović MB, Krstić DZ, Lazarevićć-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013; 11(3): 315-35.
[http://dx.doi.org/10.2174/1570159X11311030006] [PMID: 24179466]
[24]
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: A network meta-analysis. Cochrane Database Syst Rev 2019; 1465-858.
[http://dx.doi.org/10.1002/14651858.CD013306]
[25]
Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134(1): 8-25.
[http://dx.doi.org/10.1016/j.pharmthera.2011.12.002] [PMID: 22198801]
[26]
Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; (127): 45-63.
[PMID: 12139367]
[27]
Wollen KA. Alzheimer's Disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, With a Discussion of Treatment Strategies From the Perspective of Patients and Practitioners. Altern Med Rev 201 15(3): 223-44.
[28]
Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia : A Systematic Meta-Analysis 2008; 42: 32-8.
[http://dx.doi.org/10.1345/aph.1K372]
[29]
Alva G, Cummings JL. Relative Tolerability of Alzheimer ’ s Disease Treatment 2008; 5(11): 27-636.
[30]
Tsopelas ND, Marin DB. Cholinergic Treatments of Alzheimer's Disease.Functional Neurobiology of Aging.2001 475-86. In:
[31]
Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018; 281: 139-77.
[http://dx.doi.org/10.1016/j.jconrel.2018.05.011] [PMID: 29772289]
[32]
Bonferoni MC, Rossi S, Sandri G, et al. Nanoemulsions for" Nose-to-Brain. Pharmaceutics 2019; 11(2): 1-17.
[http://dx.doi.org/10.3390/pharmaceutics11020084] [PMID: 30781585]
[33]
Gänger S, Schindowski K. Tailoring Formulations for Intranasal Nose-to-Brain Delivery : A Review on Architecture Physico Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa 2018; 10 E116.
[34]
Gadhave D, Gorain B, Tagalpallewar A, Kokare C. Intranasal teriflunomide microemulsion: An improved chemotherapeutic approach in glioblastoma. J Drug Deliv Sci Technol 2019; 51: 276-89.
[http://dx.doi.org/10.1016/j.jddst.2019.02.013]
[35]
Kim D, Kim YH, Kwon S. Enhanced nasal drug delivery efficiency by increasing mechanical loading using hypergravity. Sci Rep 2018; 8(1): 168.
[http://dx.doi.org/10.1038/s41598-017-18561-x] [PMID: 29317727]
[36]
Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv 2014; 21(2): 148-54.
[http://dx.doi.org/10.3109/10717544.2013.838014] [PMID: 24128122]
[37]
Gadhave D, Choudhury H, Kokare C. Neutropenia and leukopenia protective intranasal olanzapine-loaded lipid-based nanocarriers engineered for brain delivery. Appl Nanosci 2018; 1-18.
[38]
Choudhury H, Zakaria NFB, Tilang PAB, Tzeyung AS, Pandey M, Chatterjee B, et al. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery. J Drug Deliv Sci Technol 2019.101301
[http://dx.doi.org/10.1016/j.jddst.2019.101301]
[39]
Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010; 40(5): 385-403.
[http://dx.doi.org/10.1016/j.ejps.2010.05.003] [PMID: 20497904]
[40]
Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013; 10(7): 957-72.
[http://dx.doi.org/10.1517/17425247.2013.790887] [PMID: 23586809]
[41]
Wang Q, Zhang Y, Wong C-H, Edwin Chan HY, Zuo Z. Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling. AAPS J 2017; 20(1): 23.
[http://dx.doi.org/10.1208/s12248-017-0179-0] [PMID: 29282567]
[42]
Xi J, Zhang Z, Si XA. Improving intranasal delivery of neurological nanomedicine to the olfactory region using magnetophoretic guidance of microsphere carriers. Int J Nanomedicine 2015; 10: 1211-22.
[http://dx.doi.org/10.2147/IJN.S77520] [PMID: 25709443]
[43]
Singh K, Ahmad Z, Shakya P, Ansari VA, Kumar A. Nano formulation : A novel approach for nose to brain drug delivery Nano formulation : A novel approach for nose to brain drug delivery 2016; 2016; 208-15.
[44]
Bhise SB, Yadav AV, Avachat AM, Malayandi R. Bioavailability of intranasal drug delivery system. Asian Journal of Pharmaceutics 2008; 2: 201-15.
[http://dx.doi.org/10.4103/0973-8398.45032]
[45]
Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci 2018; 195: 44-52.
[http://dx.doi.org/10.1016/j.lfs.2017.12.025] [PMID: 29277310]
[46]
Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release 2017; 268: 364-89.
[http://dx.doi.org/10.1016/j.jconrel.2017.09.001] [PMID: 28887135]
[47]
Umeda T, Tanaka A, Sakai A, Yamamoto A, Sakane T, Tomiyama T. Intranasal rifampicin for Alzheime's disease prevention. Alzheimers Dement (N Y) 2018; 4: 304-13.
[http://dx.doi.org/10.1016/j.trci.2018.06.012] [PMID: 30094330]
[48]
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127(2): 481-96.
[http://dx.doi.org/10.1016/j.neuroscience.2004.05.029] [PMID: 15262337]
[49]
Shah B, Khunt D, Misra M, Padh H. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting. Pharm Res 2018; 35(1): 8.
[http://dx.doi.org/10.1007/s11095-017-2279-z] [PMID: 29294189]
[50]
Gonçalves J, Bicker J, Gouveia F, et al. Nose-to-brain delivery of levetiracetam after intranasal administration to mice. Int J Pharm 2019; 564: 329-39.
[http://dx.doi.org/10.1016/j.ijpharm.2019.04.047] [PMID: 31015006]
[51]
Khan K, Aqil M, Imam SS, et al. Ursolic acid loaded intra nasal nano lipid vesicles for brain tumour: Formulation, optimization, in-vivo brain/plasma distribution study and histopathological assessment. Biomed Pharmacother 2018; 106: 1578-85.
[http://dx.doi.org/10.1016/j.biopha.2018.07.127] [PMID: 30119233]
[52]
Pailla SR, Talluri S, Rangaraj N, et al. Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats. Daru 2019; 27(2): 541-56.
[http://dx.doi.org/10.1007/s40199-019-00281-4] [PMID: 31256410]
[53]
Kaur S, Manhas P, Swami A, Bhandari R, Sharma KK, Jain R, et al. Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues. Chem Eng J 2018; 346: 630-9.
[http://dx.doi.org/10.1016/j.cej.2018.03.176]
[54]
Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. Nanotechnology 2014; 25(48)485102
[http://dx.doi.org/10.1088/0957-4484/25/48/485102] [PMID: 25392203]
[55]
Abdou EM, Kandil SM, Miniawy HMFE. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int J Pharm 2017; 529(1-2): 667-77.
[http://dx.doi.org/10.1016/j.ijpharm.2017.07.030] [PMID: 28729175]
[56]
Hanafy AS, Farid RM, Helmy MW, ElGamal SS. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. Drug Deliv 2016; 23(8): 3111-22.
[http://dx.doi.org/10.3109/10717544.2016.1153748] [PMID: 26942549]
[57]
Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer's Disease Therapy and Prevention Strategies. Annu Rev Med 2017; 68: 413-30.
[http://dx.doi.org/10.1146/annurev-med-042915-103753] [PMID: 28099083]
[58]
Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheime's disease. Drug Deliv 2018; 25(1): 307-20.
[http://dx.doi.org/10.1080/10717544.2018.1428243] [PMID: 29350055]
[59]
Esfahani DR, Tangen KM, Sadeh M, Seksenyan A, Neisewander BL, Mehta AI, et al. Systems engineers role in biomedical research. Convection-enhanced drug delivery. Computer-Aided Chem Eng 2018; 271-302.
[http://dx.doi.org/10.1016/B978-0-444-63964-6.00009-X]
[60]
Tosi G, Musumeci T, Ruozi B, Carbone C, Belletti D, Pignatello R, et al. The "fate" of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system. J Drug Deliv Sci Technol 2016; 32: 66-76.
[http://dx.doi.org/10.1016/j.jddst.2015.07.007]
[61]
Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm 2019; 565: 509-22.
[http://dx.doi.org/10.1016/j.ijpharm.2019.05.042] [PMID: 31102804]
[62]
Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. J Drug Target 2015; 23(9): 775-88.
[http://dx.doi.org/10.3109/1061186X.2015.1020809] [PMID: 25758751]
[63]
Antimisiaris SG, Mourtas S, Markoutsa E, Skouras A, Papadia K. Nanoparticles for Diagnosis and/or Treatment of Alzheime's Disease. Hoboken, NJ, USA. Advanced Healthcare Materials 2014 pp; 87-179.
[64]
Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64(7): 686-700.
[http://dx.doi.org/10.1016/j.addr.2011.10.007] [PMID: 22100125]
[65]
Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379(1): 146-57.
[http://dx.doi.org/10.1016/j.ijpharm.2009.06.019] [PMID: 19555750]
[66]
Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319-27.
[http://dx.doi.org/10.1016/S1359-0286(02)00117-1]
[67]
Khan A, Usman M. Early diagnosis of Alzheimer’s disease using machine learning techniques. IC3K 2015 : 7th International Joint Conference on Knowledge Discovery, Knowledge Engineering and Knowledge Management.
[68]
Wen MM, El-Salamouni NS, El-Refaie WM, et al. Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges. J Control Release 2017; 245: 95-107.
[http://dx.doi.org/10.1016/j.jconrel.2016.11.025] [PMID: 27889394]
[69]
Aliev G, Ashraf GM, Tarasov VV, et al. Alzheime's Disease - Future Therapy Based on Dendrimers. Curr Neuropharmacol 2019; 17(3): 288-94.
[http://dx.doi.org/10.2174/1570159X16666180918164623] [PMID: 30227819]
[70]
Kesharwani P, Choudhury H, Meher JG, Pandey M, Gorain B. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog Mater Sci Pergamon 2019; 103: 484-508.
[http://dx.doi.org/10.1016/j.pmatsci.2019.03.003]
[71]
Gorain B, Choudhury H, Pandey M, Nair AB, Iqbal Mohd Amin MC, Molugulu N, et al. Dendrimer-Based Nanocarriers in Lung Cancer TherapyNanotechnology-Based Target Drug Deliv Syst Lung Cancer. Academic Press 2019; pp. 161-92.
[http://dx.doi.org/10.1016/B978-0-12-815720-6.00007-1]
[72]
Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res 2013; 30(10): 2499-511.
[http://dx.doi.org/10.1007/s11095-013-1156-7] [PMID: 23959851]
[73]
Gorain B, Choudhury H, Pandey M, Mohd Amin MCI, Singh B, Gupta U, et al. Dendrimers as Effective Carriers for the Treatment of Brain Tumor. Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors 2018; pp. 267-305.
[http://dx.doi.org/10.1016/B978-0-12-812218-1.00010-5]
[74]
Gorain B, Tekade M, Kesharwani P, Iyer AK, Kalia K, Tekade RK. The use of nanoscaffolds and dendrimers in tissue engineering. Drug Discov Today 2017; 22(4): 652-64.
[http://dx.doi.org/10.1016/j.drudis.2016.12.007] [PMID: 28219742]
[75]
Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun 2006; 345(1): 21-8.
[http://dx.doi.org/10.1016/j.bbrc.2006.04.041] [PMID: 16674918]
[76]
Kumar Thakur A, Kamboj P, Goswami K, Ahuja K. Pathophysiology and management of alzheimer's disease: an overview. J Anal Pharm Res 2018; 9: 226-35.
[http://dx.doi.org/10.15406/japlr.2018.07.00230]
[77]
Klementieva O, Benseny-Cases N, Gella A, Appelhans D, Voit B, Cladera J. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity. Biomacromolecules 2011; 12(11): 3903-9.
[http://dx.doi.org/10.1021/bm2008636] [PMID: 21936579]
[78]
Klementieva O, Aso E, Filippini D, et al. Effect of poly(propylene imine) glycodendrimers on β-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheime's disease. Biomacromolecules 2013; 14(10): 3570-80.
[http://dx.doi.org/10.1021/bm400948z] [PMID: 24004423]
[79]
Xie H, Li L, Sun Y, et al. An available strategy for nasal brain transport of nanocomposite based on PAMAM dendrimers via in situ gel. Nanomaterials (Basel) 2019; 9(2)E147
[http://dx.doi.org/10.3390/nano9020147] [PMID: 30682799]
[80]
Aso E, Martinsson I, Appelhans D, et al. Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine (Lond) 2019; 17: 198-209.
[http://dx.doi.org/10.1016/j.nano.2019.01.010] [PMID: 30708052]
[81]
Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010; 624: 163-75.
[http://dx.doi.org/10.1007/978-1-60761-609-2_11] [PMID: 20217595]
[82]
Silva AC, Gonzàlez-Mira E, Lobo JM, Amaral MH. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheime's and schizophrenia. Curr Pharm Des 2013; 19(41): 7185-95.
[http://dx.doi.org/10.2174/138161281941131219123329] [PMID: 23489198]
[83]
Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2013; 166(2): 182-94.
[http://dx.doi.org/10.1016/j.jconrel.2012.12.013] [PMID: 23262199]
[84]
Patel A, Patel M, Yang X, Mitra AK. Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett 2014; 21(11): 1102-20.
[http://dx.doi.org/10.2174/0929866521666140807114240] [PMID: 25106908]
[85]
Luppi B, Bigucci F, Corace G, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 2011; 44(4): 559-65.
[http://dx.doi.org/10.1016/j.ejps.2011.10.002] [PMID: 22009109]
[86]
Wong LR, Ho PC. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheime's disease. J Pharm Pharmacol 2018; 70(1): 59-69.
[http://dx.doi.org/10.1111/jphp.12836] [PMID: 29034965]
[87]
Hanafy AS, Farid RM, ElGamal SS. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 2015; 41(12): 2055-68.
[http://dx.doi.org/10.3109/03639045.2015.1062897] [PMID: 26133084]
[88]
Sunena, Singh SK, Mishra DN. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Curr Drug Deliv 2018; 16: 51-8.
[http://dx.doi.org/10.2174/1567201815666181004094707]
[89]
Bhavna MS, Md S, Ali M, et al. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int J Biol Macromol 2014; 67: 418-25.
[http://dx.doi.org/10.1016/j.ijbiomac.2014.03.022] [PMID: 24705169]
[90]
Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. Piperine—The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. Compr Rev Food Sci Food Saf 2017; 16: 124-40.
[http://dx.doi.org/10.1111/1541-4337.12246]
[91]
Wang C, Cai Z, Wang W, et al. Piperine attenuates cognitive impairment in an experimental mouse model of sporadic Alzheimer's disease. J Nutr Biochem 2019; 70: 147-55.
[http://dx.doi.org/10.1016/j.jnutbio.2019.05.009] [PMID: 31207354]
[92]
Elnaggar YSR, Etman SM, Abdelmonsif DA, Abdallah OY. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity. J Pharm Sci 2015; 104: 3544-56.
[http://dx.doi.org/10.1002/jps.24557]
[93]
Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012; 47(1): 6-15.
[http://dx.doi.org/10.1016/j.ejps.2012.04.013] [PMID: 22561106]
[94]
Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids Surf B Biointerfaces 2017; 159: 629-38.
[http://dx.doi.org/10.1016/j.colsurfb.2017.08.031] [PMID: 28865359]
[95]
Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci 2016; 92: 224-34.
[http://dx.doi.org/10.1016/j.ejps.2016.05.012] [PMID: 27185298]
[96]
Zhang C, Chen J, Feng C, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int J Pharm 2014; 461(1-2): 192-202.
[http://dx.doi.org/10.1016/j.ijpharm.2013.11.049] [PMID: 24300213]
[97]
Meng Q, Wang A, Hua H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Int J Nanomedicine 2018; 13: 705-18.
[http://dx.doi.org/10.2147/IJN.S151474] [PMID: 29440896]
[98]
Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters. Eur J Pharm Sci 2015; 78: 54-66.
[http://dx.doi.org/10.1016/j.ejps.2015.07.002] [PMID: 26143262]
[99]
Alexander A, Saraf S. Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer's disease. Neural Regen Res 2018; 13(12): 2102-4.
[http://dx.doi.org/10.4103/1673-5374.241458] [PMID: 30323136]
[100]
Wen Z, Lin J, Su J, Zheng Z, Chen Q, Chen L. Influences of trehalose-modification of solid lipid nanoparticles on drug loading. Eur J Lipid Sci Technol 2017; 1191600364
[http://dx.doi.org/10.1002/ejlt.201600364]
[101]
Choudhury H, Maheshwari R, Pandey M, Tekade M, Gorain B, Tekade RK. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug Etoposide. Mater Sci Eng C 2020; 106110275
[http://dx.doi.org/10.1016/j.msec.2019.110275] [PMID: 31753398]
[102]
Choudhury H, Pandey M, Yin TH, et al. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology. Mater Sci Eng C 2019; 101: 596-613.
[http://dx.doi.org/10.1016/j.msec.2019.04.005] [PMID: 31029353]
[103]
Wong KH, Riaz MK, Xie Y, et al. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. Int J Mol Sci 2019; 20(2): 381.
[http://dx.doi.org/10.3390/ijms20020381] [PMID: 30658419]
[104]
Hong S-S, Oh KT, Choi H-G, Lim S-J. Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives. Pharmaceutics 2019; 11(10): 540.
[http://dx.doi.org/10.3390/pharmaceutics11100540] [PMID: 31627301]
[105]
Zheng X, Shao X, Zhang C, et al. Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer's Disease. Pharm Res 2015; 32(12): 3837-49.
[http://dx.doi.org/10.1007/s11095-015-1744-9] [PMID: 26113236]
[106]
Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008; 58(3): 287-97.
[http://dx.doi.org/10.2478/v10007-008-0014-3] [PMID: 19103565]
[107]
Yang Z-Z, Zhang Y-Q, Wang Z-Z, Wu K, Lou J-N, Qi X-R. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 2013; 452(1-2): 344-54.
[http://dx.doi.org/10.1016/j.ijpharm.2013.05.009] [PMID: 23680731]
[108]
Al Asmari AK, Ullah Z, Tariq M, Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016; 10: 205-15.
[PMID: 26834457]
[109]
Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 2012; 34(2): 272-9.
[http://dx.doi.org/10.1016/j.etap.2012.04.012] [PMID: 22613079]
[110]
VV S. OG B, SM S. Comparative Analysis of Nasal Therapy with Soluble and Liposomal Forms of Curcumin on Rats with Alzheimer's Disease Model. J Alzheime's Dis Park 2017; 07: 1-6.
[111]
Corace G, Angeloni C, Malaguti M, et al. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 2014; 24(4): 323-35.
[http://dx.doi.org/10.3109/08982104.2014.899369] [PMID: 24807822]
[112]
Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 2018; 128: 337-62.
[http://dx.doi.org/10.1016/j.ejpb.2018.05.009] [PMID: 29733950]
[113]
Fonseca-Santos B, Gremião MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. Int J Nanomedicine 2015; 10: 4981-5003.
[http://dx.doi.org/10.2147/IJN.S87148] [PMID: 26345528]
[114]
Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. Colloids Surf B Biointerfaces 2017; 152: 296-301.
[http://dx.doi.org/10.1016/j.colsurfb.2017.01.031] [PMID: 28126681]
[115]
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7(6): 483-93.
[http://dx.doi.org/10.1016/S1474-4422(08)70090-5] [PMID: 18450517]
[116]
Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model. J Drug Target 2013; 21(3): 300-11.
[http://dx.doi.org/10.3109/1061186X.2012.747529] [PMID: 23231324]
[117]
Sood S, Jain K, Gowthamarajan K. Curcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer's disease model. Alzheimers Dement 2013; 9: 299.
[http://dx.doi.org/10.1016/j.jalz.2013.05.609]
[118]
Choudhury H, Gorain B, Chatterjee B, Mandal UK, Sengupta P, Tekade RK. Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route. Curr Pharm Des 2017; 23(17): 2504-31.
[http://dx.doi.org/10.2174/1381612822666161201143600] [PMID: 27908273]
[119]
Choudhury H, Pandey M, Gorain B, Chatterjee B, Madheswaran T, Md S, et al. Nanoemulsions as Effective Carriers for the Treatment of Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer 2019; pp. 217-47.
[http://dx.doi.org/10.1016/B978-0-12-815720-6.00009-5]
[120]
Pandey M, Choudhury H, Yeun OC, et al. Perspectives of Nanoemulsion Strategies in The Improvement of Oral, Parenteral and Transdermal Chemotherapy. Curr Pharm Biotechnol 2018; 19(4): 276-92.
[http://dx.doi.org/10.2174/1389201019666180605125234] [PMID: 29874994]
[121]
Choudhury H, Gorain B, Karmakar S, et al. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. Int J Pharm 2014; 460(1-2): 131-43.
[http://dx.doi.org/10.1016/j.ijpharm.2013.10.055] [PMID: 24239580]
[122]
Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target 2005; 13(5): 317-24.
[http://dx.doi.org/10.1080/10611860500246217] [PMID: 16199375]
[123]
Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358(1-2): 285-91.
[http://dx.doi.org/10.1016/j.ijpharm.2008.03.029] [PMID: 18455333]
[124]
Nasr M. Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Deliv 2016; 23(4): 1444-52.
[http://dx.doi.org/10.3109/10717544.2015.1092619] [PMID: 26401600]
[125]
Jaiswal M, Kumar A, Sharma S. Nanoemulsions loaded Carbopol® 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in–vitro and ex–vivo permeation study. J Pharm Investig 2016; 46: 79-89.
[http://dx.doi.org/10.1007/s40005-016-0228-1]
[126]
Espinoza LC, Vacacela M, Clares B, Garcia ML, Fabrega MJ, Calpena AC. Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization. CNS Neurol Disord Drug Targets 2018; 17(1): 43-53.
[http://dx.doi.org/10.2174/1871527317666180104122347] [PMID: 29299992]
[127]
Singh M, Singh SP, Rachana R. Development, characterization and cytotoxicity evaluation of Gingko biloba extract (EGB761) loaded microemulsion for intra-nasal application. J Appl Pharm Sci 2017; 7: 24-034.
[http://dx.doi.org/10.7324/JAPS.2017.70104]
[128]
Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech 2014; 15(3): 694-708.
[http://dx.doi.org/10.1208/s12249-014-0088-9] [PMID: 24510526]
[129]
Olfactory Neuroepithelial Tissue of Alzheimer Disease Available at. https://clinicaltrials.gov/ct2/show/NCT02129452?term=diagnosis+AND+nasal&cond=Alzheimer+Disease&draw=2&rank=5
[130]
Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples. Available at : https://clinicaltrals.gov/ct2/show/NCT03715855?term=diagnosis+AND+nasal&cond=Alzheimer+Disease&draw=2&rank=3
[131]
Alzheimer’s Autism and Cognitive Impairment Stem Cell Treatment Study. Available at: https://clinicaltrials.gov/ct2/show/NCT03724136?term=nasal&cond=Alzheimer+Disease&draw=3&rank=19
[132]
Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl Med 2018; 7(4): 333-41.
[http://dx.doi.org/10.1002/sctm.17-0042] [PMID: 29405603]
[133]
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days. Available at: https://clinicaltrals.gov/ct2/show/NCT01547169?term=nasal&cond=Alzheimer+Disease&draw=2&;rank=2

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy